120 related articles for article (PubMed ID: 22576683)
1. Clinicopathological characteristics of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency.
Kanoh Y; Ohtani H; Egawa S; Baba S; Akahoshi T
Int J Oncol; 2012 Jul; 41(1):39-45. PubMed ID: 22576683
[TBL] [Abstract][Full Text] [Related]
2. Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with alpha2-macroglobulin deficiency.
Kanoh Y; Ohtani H; Egawa S; Baba S; Akahoshi T
Clin Lab; 2012; 58(3-4):217-25. PubMed ID: 22582494
[TBL] [Abstract][Full Text] [Related]
3. Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency.
Kanoh Y; Ohtani H; Egawa S; Baba S; Akahoshi T
Int J Oncol; 2011 Dec; 39(6):1553-8. PubMed ID: 21894431
[TBL] [Abstract][Full Text] [Related]
4. Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency.
Kanoh Y; Ohara T; Egawa S; Baba S; Akahoshi T
J Clin Lab Anal; 2008; 22(4):302-6. PubMed ID: 18623104
[TBL] [Abstract][Full Text] [Related]
5. Associations of IgG N-linked oligosaccharide chains and proteases in sera of prostate cancer patients with and without alpha2-macroglobulin deficiency.
Kanoh Y; Egawa S; Baba S; Akahoshi T
J Clin Lab Anal; 2009; 23(2):125-31. PubMed ID: 19288446
[TBL] [Abstract][Full Text] [Related]
6. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
[TBL] [Abstract][Full Text] [Related]
7. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
[TBL] [Abstract][Full Text] [Related]
8. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin.
España F; Sánchez-Cuenca J; Estellés A; Gilabert J; Griffin JH; Heeb MJ
Clin Chem; 1996 Apr; 42(4):545-50. PubMed ID: 8605671
[TBL] [Abstract][Full Text] [Related]
9. [Concentrations of free form and complex form of prostate-specific antigen in serum of alpha 2 macroglobulin deficient patients with prostatic carcinoma].
Kanoh Y; Jimbo S; Shibuya M; Matsuyama N; Mashiko T; Tanaka T; Egawa S; Ohtani H
Rinsho Byori; 1998 Sep; 46(9):923-9. PubMed ID: 9800478
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
12. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
[TBL] [Abstract][Full Text] [Related]
15. Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies.
Falsaperla M; Morgia G; Giammusso B; Condorelli SV; Saita A; Marchese F; Spampinato A; Motta M
Prostate Cancer Prostatic Dis; 2003; 6(1):45-9. PubMed ID: 12664064
[TBL] [Abstract][Full Text] [Related]
16. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.
Morote J; Trilla E; Esquena S; Abascal JM; Reventos J
Int J Cancer; 2004 Mar; 108(6):877-81. PubMed ID: 14712491
[TBL] [Abstract][Full Text] [Related]
17. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
[TBL] [Abstract][Full Text] [Related]
18. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
19. Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients.
Makis AC; Hatzimichael EC; Mavridis A; Bourantas KL
Acta Haematol; 2000; 104(4):164-8. PubMed ID: 11279305
[TBL] [Abstract][Full Text] [Related]
20. [Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis].
Kanoh Y; Ohtani H; Koshiba K
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Feb; 20(1):30-43. PubMed ID: 9105163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
